- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04601974
Lentiviral Gene Therapy for Epilepsy
Phase I/IIa, First-in-human, Open-label, Single-site Trial of In-vivo Lentiviral Engineered Potassium (K+) Channel (EKC) Gene Therapy for Refractory Epilepsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epilepsy affects about 1% of the population. One third of affected individuals continue to have seizures despite optimal medication. The only realistic prospect of seizure freedom, feasible in very few cases, is surgery to remove the brain area where seizures arise.
Patients with refractory neocortical epilepsy who are being evaluated for surgical resection of the seizure focus will be invited to join the trial. The non-integrating lentiviral vector, which has been engineered to deliver an engineered potassium channel, will be administered via intracerebral infusion to the area scheduled for resection.
The primary objective in this study is to test the safety of the lentiviral gene therapy treatment, including the surgical procedures required for vector administration. Secondary objectives will look at delayed onset adverse events and indicators of efficacy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Senior Clinical Project Manager
- Phone Number: +44(0)2031088954
- Email: ekctrial@ucl.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
SCREENING/PRE-CONSENT:
- Female and male patients with refractory focal epilepsy
- Aged ≥ 18 years (no upper age limit but deemed medically fit for surgery with a life expectancy of at least 5 years)
- Patient lives within 1 hour of transfer to an acute neurosurgical unit
Being considered for resective brain surgery (to remove the epileptogenic focus) based on first-stage preoperative assessments carried out as part of routine clinical care within 2 years of registration, showing:
4.1. Absence of vascular brain lesions or vascular malformations and/or cancer in the resection area (as confirmed on MRI) 4.2. Absence of active, untreated psychiatric disease in the opinion of the treating clinician (as confirmed by neuropsychiatric assessment) 4.3. Patient requires second-stage intracranial EEG investigations to be carried out via burr hole surgery to further assess eligibility for resective brain surgery
PRE-REGISTRATION:
- Patient deemed clinically suitable for resective brain surgery (i.e. a single region of seizure onset in the neocortex has been identified, and it does not overlap with areas necessary for critical functions such as language), as confirmed by intracranial EEG investigations
- Patients who are women of childbearing potential (WOCBP), or male patients with female partners who are WOCBP or pregnant must agree to use highly effective methods of contraception from the time consent is signed until three months after treatment. Men (if applicable), must also advise their female partners regarding contraceptive requirements as listed for female patients who are WOCBP or pregnant.
- Able and willing to give written informed consent to join trial
Exclusion Criteria:
- Not deemed clinically suitable for resective brain surgery (e.g. because of failure to identify a single region of seizure onset in the neocortex, region is too extensive or the region overlaps with areas necessary for critical functions such as language), as confirmed by intracranial EEG investigations
- Vascular brain lesions or vascular malformations in area of planned resection
- Detection of active cancer or on systemic treatment for cancer
- Known or suspected HIV infection (confirmed by PCR test) and/or taking antiretroviral therapy
- Patient deemed medically unfit for anaesthesia and surgery
- Active, untreated psychiatric disease in the opinion of the treating clinician
- Concurrent and/or recent involvement in another clinical trial of an investigational medicinal product (within last 3 months)
- Females who are pregnant (confirmed by serum/urine ß-HCG) or actively breast-feeding
- Known allergies to excipients of lentiviral gene therapy
- Patient unlikely to cooperate with a 5-year follow-up; medical or psychological condition at the discretion of the investigator which would not permit compliance with the protocol or meaningful written informed consent
- Any other known condition which is assessed as an intolerable risk by the investigator upon inclusion in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: lentiviral gene therapy treatment (Intervention Arm)
Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
|
lentiviral gene therapy to treat drug resistant epilepsy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety during the First Year (for adverse events related to lentiviral gene therapy only)
Time Frame: At 6 weeks, 3 months, 6 months and 12 months after trial treatment
|
Number and severity of all adverse events (graded using CTCAE v5.0) in patients deemed causally related to lentiviral gene therapy
|
At 6 weeks, 3 months, 6 months and 12 months after trial treatment
|
Safety during the First Year (for adverse events causally related to investigational surgical procedures only)
Time Frame: At 6 weeks, 3 months, 6 months and 12 months after trial treatment
|
Number and severity of all adverse events (graded using CTCAE v5.0) deemed causally related to any of the investigational surgical trial procedures required for vector administration
|
At 6 weeks, 3 months, 6 months and 12 months after trial treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-Term Safety (for adverse events related to lentiviral gene therapy only)
Time Frame: From 1 to 5 years after treatment
|
Number of serious adverse events (graded using CTCAE v5.0) in patients related to the lentiviral gene therapy
|
From 1 to 5 years after treatment
|
Long-Term Safety (for adverse events causally related to investigational surgical procedures only)
Time Frame: From 1 to 5 years after treatment
|
Number of serious adverse events (graded using CTCAE v5.0) in patients related to the investigational surgical procedures required for vector administration
|
From 1 to 5 years after treatment
|
Clinical Indicators of Efficacy and Tolerability
Time Frame: Measured at 6 weeks, 3 months, 6 months, and 12 months/1 year after trial treatment
|
Seizure frequency and severity over preceeding 4 weeks
|
Measured at 6 weeks, 3 months, 6 months, and 12 months/1 year after trial treatment
|
Clinical Indicators of Efficacy and Tolerability
Time Frame: Measured at 12 months/1 year, 2 years, 3 years, 4 years and 5 years after trial treatment
|
Seizure frequency and severity (using IALE outcomes scale)
|
Measured at 12 months/1 year, 2 years, 3 years, 4 years and 5 years after trial treatment
|
Clinical Indicators of Efficacy and Tolerability
Time Frame: at 3, 6, or 12 months, or at 2, 3, 4, and 5 years after trial treatment
|
Proportion of patients who have had surgical resection
|
at 3, 6, or 12 months, or at 2, 3, 4, and 5 years after trial treatment
|
Cortical excitability
Time Frame: at 6 months after trial treatment (only for patients in TMS study)
|
Cortical excitability (assessed using TMS, EMG, and high-density EEG)
|
at 6 months after trial treatment (only for patients in TMS study)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18/0202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Resistant Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Mansoura University HospitalUnknown
-
Nova Scotia Health AuthorityNot yet recruitingEpilepsy, Drug ResistantCanada
-
The Hospital for Sick ChildrenSt. Justine's HospitalCompletedEpilepsy, Drug ResistantCanada
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Recruiting
-
Instituto Mexicano del Seguro SocialCompletedEpilepsy, Drug ResistantMexico
-
MGC Pharmaceuticals d.o.oNot yet recruitingResistant Epilepsy, Drug | Adolescent Epilepsy | Children Epilepsy | Children and Adolescents With Resistant EpilepsiesIsrael, Slovenia
-
Centre Hospitalier St AnneFondation de l'Avenir; Fondation pour les Sciences du Cerveau; Association NEUROREFSTerminatedPartial Drug-resistant EpilepsyFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; ICM Co....Recruiting
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingEpilepsy, Drug Resistant | Acupuncture TherapyVietnam
Clinical Trials on lentiviral gene therapy
-
Children's Hospital of Chongqing Medical UniversityRecruiting
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's Hospital; California Institute for Regenerative Medicine (CIRM) and other collaboratorsRecruitingGranulomatous Disease, Chronic, X-linkedUnited States
-
Pell Bio-Med Technology Co., Ltd.RecruitingDiffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3ATaiwan
-
University of ManchesterUniversity College, London; Manchester University NHS Foundation Trust; Orchard... and other collaboratorsActive, not recruitingMucopolysaccharidosis Type IIIAUnited Kingdom
-
GenethonInstitute of Child Health; Great Ormond Street Hospital for Children NHS Foundation...Completed
-
GenethonHôpital Necker-Enfants MaladesCompleted
-
National Human Genome Research Institute (NHGRI)National Institutes of Health Clinical Center (CC); National Cancer Institute... and other collaboratorsCompletedADA-SCID | Adenosine Deaminase DeficiencyUnited States
-
University of PennsylvaniaCompletedSubjects Who Have Received Lentiviral-based CART-meso TherapyUnited States
-
IRCCS San RaffaeleOrchard Therapeutics; Fondazione TelethonUnknown
-
The Methodist Hospital Research InstituteRecruitingGlioblastoma | Anaplastic AstrocytomaUnited States